Definium Therapeutics (DFTX) Equity Ratio (2019 - 2026)

Definium Therapeutics (DFTX) has 8 years of Equity Ratio data on file, last reported at 0.69 in Q1 2026.

• Quarterly Equity Ratio fell 14.13% year-over-year to 0.69 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.69 (down 14.13% YoY) and the FY2025 annual result came in at 0.76, down 5.5% from the prior year.
• Equity Ratio declined to 0.69 in Q1 2026 per DFTX's latest filing, from 0.76 in the prior quarter.
• Across five years, Equity Ratio topped out at 0.93 in Q2 2022 and bottomed at 0.55 in Q3 2025.
• The 5-year median for Equity Ratio is 0.76 (2025), against an average of 0.77.
• The widest annual swing landed in 2024, when Equity Ratio increased 27.37%; it then sank 32.77% in 2025.
• Tracing DFTX's Equity Ratio over 5 years: stood at 0.89 in 2022, then decreased by 29.33% to 0.63 in 2023, then gained by 27.37% to 0.8 in 2024, then slipped by 5.5% to 0.76 in 2025, then fell by 7.98% to 0.69 in 2026.
• Per Business Quant, the three latest DFTX Equity Ratio figures stand at 0.69 (Q1 2026), 0.76 (Q4 2025), and 0.55 (Q3 2025).

Peer Comparison